[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adrenal-incidentalomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adrenal-incidentalomas":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608176","artificial-intelligence-used-in-screening-adrenal-nodules-100608176",false,"NCT07198152","Artificial Intelligence Used in Screening Adrenal Nodules","The Application of Artificial Intelligence in Screening Adrenal Nodules in Low-dose Chest CT","Inclusion Criteria:\n\n1. The age of the population is over 18 years old, regardless of gender;\n2. Images from chest low-dose CT plain scan during routine physical examination;\n\nExclusion Criteria:\n\n1. Patients with a history of malignant tumors;\n2. Imaging images with poor quality, artifacts, etc., which make analysis impossible.",true,"ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules, we will ultimately develop an artificial intelligence software with independent intellectual property rights that is specifically designed for screening adrenal nodules in chest low-dose CT scans.",[25,26],"Adrenal Incidentalomas","Thoracic CT-scan",[28],"automatic segment; automatic classification","RECRUITING","2025-09-27",{"date":32,"type":33},"2025-09-30","ACTUAL",{"date":35,"type":33},"2025-09-01",{"date":37,"type":21},"2027-01-30",{"name":39,"class":40},"Peking University First Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100577665","phase-4-effect-of-metyrapone-on-cardiovascular-risk-factors-in-patients-with-adrenal-incidentalomas-and-cushings-syndrome-100577665","NCT06801249","Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome","\"Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Subclinical\u002FMild Cushing's Syndrome","Inclusion Criteria:\n\nInclusion criteria - run-in (phase 1)\n\n* Unilateral or bilateral adrenal nodules with benign features associated with thickening of the adrenal arms \\>5 mm on abdominal CT scan\n* SCS (detected 2 times in the 6 months before run-in) defined by the absence of catabolic signs of Cushing's syndrome in association with any of these 3 conditions:\n\n  * Cortisol levels after dexamethasone 1 mg test \\>50 nmol\u002FL associated with baseline ACTH \\\u003C10 pg\u002FmL\n  * Cortisol levels after dexamethasone 1 mg test \\>50 nmol\u002FL associated with increased nocturnal (11 pm) salivary cortisol\n  * Cortisol levels after dexamethasone 1 mg test \\>138 nmol\u002FL\n* Hypertension (BP ≥140\u002F90 mmHg and\u002For ongoing antihypertensive treatment)\n* Patients who cannot undergo surgery\n* Acquisition of informed consent.\n\nInclusion criteria - randomization (phase 2)\n\n\\- BP \\>100\u002F60 mmHg and \\\u003C130\u002F85 mmHg on antihypertensive therapy (lowest effective dose) within 6-10 months after enrollment.\n\nExclusion Criteria:\n\n* Body mass index ≥40 kg\u002Fm2\n* Pregnant or lactating women; diagnosis of pregnancy will be made by serum β-HCG assay\n* Women of childbearing age using contraceptive measures other than barrier contraception. Barrier contraceptive measures are: o Male or female condom with or without spermicide o Cervical cup, diaphragm or sponges with spermicide o Combination of male condom and cervical cup, diaphragm or sponges with spermicide (dual barrier methods)\n* Treatment with steroids in the last year before enrollment\n* Taking medications known to interfere with Metirapone\n* Known or suspected hypersensitivity to the drug or drug class under study\n* Patients with serious clinical conditions that, in the opinion of the Investigator, contraindicate the patient's participation in the study\n* Patients with primary corticosurrenal insufficiency, impaired adrenal secretion, and severe hypopituitarism\n* Patients with impaired liver function\n* Patients with untreated hypothyroidism or being treated with drugs that have an action on the hypothalamic-pituitary-adrenal axis\n* Patients with hypersensitivity to the active ingredient or any of the excipients listed in section 6.1 of the RCP - Metirapone.","75 Years",{"count":51,"type":21},50,"INTERVENTIONAL",[54],"PHASE4","Drug interventional, controlled, randomized open-label, parallel-group, multicenter study in patients with bilateral adrenal incidentalomas associated with subclinical Cushing's syndrome",[25,57],"Cushing Syndrome","2025-01-24",{"date":60,"type":33},"2025-01-30",{"date":62,"type":33},"2021-02-23",{"date":64,"type":21},"2025-02-17",{"name":66,"class":40},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3]